Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Busy Week: Firm Acquires Panitumumab Partner Abgenix, Starts BLA

Executive Summary

Amgen's acquisition of its development partner Abgenix will give the firm a stronger base to launch the metastatic colorectal cancer treatment panitumumab

You may also be interested in...



Amgen completes Abgenix acquisition

Amgen has completed its $2.2 bil. acquisition of Abgenix. The deal, inked in December, gives Amgen full ownership of metastatic colorectal cancer treatment panitumumab (1"The Pink Sheet" Dec. 19, 2005, p. 24). The companies announced March 30 that they have completed submission of the rolling panitumumab BLA...

Amgen completes Abgenix acquisition

Amgen has completed its $2.2 bil. acquisition of Abgenix. The deal, inked in December, gives Amgen full ownership of metastatic colorectal cancer treatment panitumumab (1"The Pink Sheet" Dec. 19, 2005, p. 24). The companies announced March 30 that they have completed submission of the rolling panitumumab BLA...

Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer

Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel